9,651 Shares in Medtronic PLC $MDT Bought by Essex Investment Management Co. LLC

Essex Investment Management Co. LLC purchased a new stake in Medtronic PLC (NYSE:MDT) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor purchased 9,651 shares of the medical technology company’s stock, valued at approximately $919,000.

Several other hedge funds also recently added to or reduced their stakes in the stock. Brighton Jones LLC boosted its holdings in Medtronic by 1,368.0% in the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after acquiring an additional 37,265 shares during the period. Sivia Capital Partners LLC lifted its position in shares of Medtronic by 9.6% during the second quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock worth $380,000 after purchasing an additional 381 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of Medtronic by 2.4% in the second quarter. Allspring Global Investments Holdings LLC now owns 1,176,171 shares of the medical technology company’s stock valued at $104,385,000 after purchasing an additional 27,055 shares during the period. Hazlett Burt & Watson Inc. boosted its stake in shares of Medtronic by 1,044.7% in the second quarter. Hazlett Burt & Watson Inc. now owns 870 shares of the medical technology company’s stock valued at $76,000 after purchasing an additional 794 shares during the period. Finally, Cypress Capital Group grew its holdings in Medtronic by 15.2% during the 2nd quarter. Cypress Capital Group now owns 4,501 shares of the medical technology company’s stock valued at $392,000 after purchasing an additional 593 shares in the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have commented on MDT shares. William Blair upgraded shares of Medtronic from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 6th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Medtronic in a research report on Monday, December 29th. Daiwa Securities Group boosted their price target on Medtronic from $104.00 to $117.00 and gave the stock a “buy” rating in a research note on Tuesday, November 25th. CICC Research started coverage on Medtronic in a research note on Friday, January 30th. They set an “outperform” rating for the company. Finally, Sanford C. Bernstein lifted their price objective on Medtronic from $111.00 to $112.00 and gave the stock an “outperform” rating in a report on Friday, January 9th. Sixteen equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $111.21.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic agreed to acquire CathWorks for $585 million — expands its cath-lab/FFR imaging capabilities and strengthens the cardiovascular franchise, a strategic tuck-in that could accelerate revenue and cross‑sell opportunities. Medtronic to Buy CathWorks for $585M
• Positive Sentiment: Needham upgraded MDT to a “buy” and set a $121 price target (~19% upside from current levels) — the upgrade can attract buying interest and supports near-term sentiment. Needham upgrades Medtronic (MDT)
• Positive Sentiment: Analysts and trade press note new product momentum and related rating boosts — fresh product launches/approvals bolster growth narrative and margin leverage over time. Medtronic stock gets a ratings boost on new products
• Positive Sentiment: Outlook drivers: Zacks highlights strength in Medtronic’s cardiovascular unit as a likely lift to Q3 revenue (projected ~7.3% y/y), which could offset softer EPS. Strength in Cardiovascular Unit Likely to Lift MDT’s Q3 Performance
• Neutral Sentiment: MDT is expected to report earnings this week — the print and any revised FY guidance remain the primary short-term catalyst. Medtronic (MDT) Expected to Announce Earnings on Tuesday
• Neutral Sentiment: Analyst/market narratives are shifting as Medtronic’s strategic moves and pipeline progress get priced in — read for context on repositioning and valuation. How Recent Moves Are Quietly Rewriting The Story For Medtronic (MDT)
• Neutral Sentiment: Market note: the stock recently dipped while broader markets gained — a short-term trading signal but not a fundamental verdict. Medtronic (MDT) Stock Dips While Market Gains: Key Facts
• Negative Sentiment: An antitrust verdict awarded roughly $381.7M in damages against Medtronic — this legal cost and any follow‑on litigation/settlement risk can pressure near‑term earnings and valuation multiples. A Look At Medtronic (MDT) Valuation After Major Antitrust Verdict And US$381.7m Damages Award

Medtronic Stock Down 0.3%

Shares of Medtronic stock opened at $101.37 on Wednesday. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. The firm has a market cap of $129.96 billion, a P/E ratio of 27.32, a P/E/G ratio of 2.68 and a beta of 0.71. Medtronic PLC has a fifty-two week low of $79.55 and a fifty-two week high of $106.33. The business has a 50-day moving average price of $99.36 and a 200 day moving average price of $96.28.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. The company had revenue of $8.96 billion for the quarter, compared to the consensus estimate of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.Medtronic’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter last year, the business posted $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, sell-side analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were paid a dividend of $0.71 per share. The ex-dividend date was Friday, December 26th. This represents a $2.84 annualized dividend and a yield of 2.8%. Medtronic’s dividend payout ratio (DPR) is 76.55%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).